DERL1 and cancer: Furthermore, high-expression Derlin-1 had notably lower bladder recurrence-free survival (p = 0.005; Figure 1B), progression-free survival (p = 0.001; Figure 1C) and cancer-specific survival (p = 0.001; Figure 1D) than those with a low Derlin-1 expression level.